Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT04381221
Other study ID # MyPal4Kids
Secondary ID DRKS000214588258
Status Recruiting
Phase
First received
Last updated
Start date December 22, 2020
Est. completion date September 2022

Study information

Verified date March 2022
Source Centre for Research and Technology Hellas
Contact Norbert Graf, Professor MD
Phone +49 68411628411
Email graf@uks.eu
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

The main aim of the study is the evaluation of the feasibility of comprehensive service which has been developed while considering patient-orientated needs. With regard to the study, apps have been developed for both groups of participants, parents and their child which suffers from cancer. These apps aim at supporting the documentation and communication of the own condition. This includes for example a video game which can be played via tablet or smartphone in which questions appear addressing the personally perceived burden by children amongst other things. Participants of the study are children between 6 and 17 years of age which suffer from leukemia or tumors. Further participants of the study are at least one of the patient's parents. It is an observational study. Within the course of the study, the usual treatment is not altered actively by the study, it is, however, supplemented by questionnaires which will be analyzed being anonymized after the end of the study running time.


Description:

The study is designed as observational prospective feasibility study. The main objective is to assess the feasibility of a comprehensive, patient-centred service for palliative care in children with cancer by adapting and advancing ePRO systems, which aim at supporting the communication between the patients, their parents and the treating medical healthcare professionals. Participants of the study are pediatric oncology patients between 6 and 17 years of age and at least one of their parents, receiving treatment at one of the participating clinical centers due to leukemia or solid tumors. With regard to the study, apps have been developed for both groups of participants, which includes inter alia a game in which questions about burden considering symptoms can be answered by the children.


Recruitment information / eligibility

Status Recruiting
Enrollment 100
Est. completion date September 2022
Est. primary completion date September 2022
Accepts healthy volunteers No
Gender All
Age group 6 Years to 17 Years
Eligibility Inclusion Criteria for Children: - 6-17 years of age - Diagnosed with paediatric leukaemia or solid cancer in the past 12 months - Receiving anti-cancer treatment at one of the participating clinical site - Have age-appropriate speaking, reading and comprehension skills in either the German or the Czech language - Provide signed + informed consent from parents or legal representative and the assent form by all children from the age of 14 years. These documents had been evaluated positively by IEC. - Access to an internet connection and mobile device (e.g. smartphone or tablet) Inclusion Criteria for Parents: - Parent(s) with a child eligible for the study, as per the inclusion and exclusion-criteria - Ability to speak, read and understand German or Czech language - Provide signed informed consent by parent(s). These documents had been evaluated positively by IEC. - Access to an internet connection and mobile device (e.g. smartphone or tablet) Exclusion Criteria for Children: • Anyone who is not able to participate in the study according to the clinical judgment of the site chief investigator or any other authorized person of the research team. This judgment has to be documented for each child not being enrolled. Exclusion Criteria for Parents: • Anyone who is not able to participate in the study according to the clinical judgment of the site chief investigator or any other authorized person of the research team. This judgment has to be documented for each parent not being enrolled.

Study Design


Related Conditions & MeSH terms


Locations

Country Name City State
Czechia University Hospital Brno Brno Mähren
Germany Medical School Hannover Hannover Lower Saxony
Germany Saarland University Homburg Saarland

Sponsors (4)

Lead Sponsor Collaborator
Centre for Research and Technology Hellas Brno University Hospital, Hannover Medical School, Universität des Saarlandes

Countries where clinical trial is conducted

Czechia,  Germany, 

Outcome

Type Measure Description Time frame Safety issue
Primary Recruitment rate, defined as percentage of patients eligible for the study from all patients who were screened for the study. This contributes to the primary study objective: to assess the feasibility and acceptability of a comprehensive, patient-centred service for palliative care and pediatric oncology by adapting and advancing ePRO systems. Further to identify differences between the participating clinical medical centers. This outcome measure also contributes to the secondary objective which is to determine the usage and evaluation of the MyPal apps including the gamified ePRO by children with cancer. Regularly each month in the course of 6-month course of study enrollment.
Primary Participation rate, defined as percentage of recruited patients who completed at least 70% of the scheduled questionnaires for 6 months out of all patients eligible for the study This contributes to the primary study objective: to assess the feasibility and acceptability of a comprehensive, patient-centred service for palliative care in children with cancer by adapting and advancing ePRO systems. Further to identify differences between the participating clinical medical centers. This outcome measure also contributes to the secondary objective which is to determine the usage and evaluation of the MyPal apps including the gamified ePRO by children with cancer. Regularly each month in the course of 6-month course of study enrollment
Primary Adherence rate to the different components of the MyPal services by documentation of user behavior and qualitative analysis This contributes to the primary study objective: to assess the feasibility and acceptability of a comprehensive, patient-centred service for palliative care in children with cancer by adapting and advancing ePRO systems. Further to identify differences between the participating clinical medical centers. This outcome measure also contributes to the secondary objective which is to determine the usage and evaluation of the MyPal apps including the gamified ePRO by children with cancer. Regularly each month in the course of 6-month course of study enrollment
Primary Premature discontinuation rate, defined as percentage of recruited patients who have not been followed-up until the end of 6-month course of study enrollment (withdrawal, death or less than 70% completed questionnaires) This contributes to the primary study objective: to assess the feasibility and acceptability of a comprehensive, patient-centred service for palliative care in children with cancer by adapting and advancing ePRO systems. Further to identify differences between the participating clinical medical centers. This outcome measure also contributes to the secondary objective which is to determine the usage and evaluation of the MyPal apps including the gamified ePRO by children with cancer. Regularly each month in the course of 6-month course of study enrollment
Primary System Usability Scale Min Value: 0, Max Value: 100, higher scores indicate a better outcome. Quantitative data to assess the feasibility and acceptability of a comprehensive, patient-centred service for palliative care in children with cancer by adapting and advancing ePRO systems. Further to identify differences between the participating clinical medical centers. This outcome measure also contributes to the secondary objective which is to determine the usage and evaluation of the MyPal apps including the gamified ePRO by children with cancer. At the end of the 6-month course of study enrollment
Primary Structured Interviews and Focus Groups Qualitative data to assess the feasibility and acceptability of a comprehensive, patient-centred service for palliative care in children with cancer by adapting and advancing ePRO systems. Further to identify differences between the participating clinical medical centers. This outcome measure also contributes to the secondary objective which is to determine the usage and evaluation of the MyPal apps including the gamified ePRO by children with cancer. At the end of the 6-month course of study enrollment
Secondary Digital adaption of the Mini-SSpedi / SSPedi questionnaires as ePRO. Min Value: 0, Max Value: 5, higher scores indicate a worse outcome. To assess children's symptom burden through an in-game ePRO and optionally as standalone ePRO which can be completed outside the serious game.Further, this contributes to the evidence-base of the effectiveness of ePROs in palliative and supportive care for children with cancer. Once at baseline and several times a week during the 6-month course of study enrollment. The frequency of single questions depends on severity of reported symptom burden.
Secondary PedsQL(TM) Cancer Module questionnaire as ePRO. Min Value: 0, Max Value: 100, higher scores indicate a better outcome. To demonstrate the appropriateness and acceptability of measures of quality of life of children with cancer. Once at baseline and each month during the 6-month course of study enrollment.
Secondary EORTC PATSAT C-33 questionnaire, adapted appropriately as ePRO to consider parents' perception. Min Value: 0, Max Value: 100, higher scores indicate a better outcome. To demonstrate the appropriateness and acceptability of measures of parents' satisfaction with cancer care, i.e. the parents' perception of the quality of medical and nursing care as well as the evaluation of the care's organization and the oncology department services. Furthermore to determine usage and evaluation of the MyPal apps including the gamified ePRO for children with cancer. Once at baseline and each month during the 6-month course of study enrollment.
Secondary Impact on Family Scale questionnaire as ePRO. Higher scale scores indicate a worse outcome. To demonstrate the appropriateness and acceptability of measures of the impact of pediatric illness on the family, specifically with regards to financial impact, family-social impact and personal strain. Once at baseline and each month during the 6-month course of study enrollment.
Secondary EQ-5D-3L questionnaire as ePRO. Min Value: 11111, Max Value: 33333, higher scores indicate a worse outcome. To demonstrate the appropriateness and acceptability of measures of parents' quality of life having children with cancer. It will be evaluated with regard to the five dimensions: mobility, self-care, usual activities, pain/discomfort and anxiety/depression. Once at baseline and each month during the 6-month course of study enrollment.
Secondary Uniquely developed web-based online questionnaire. Higher scores indicate a worse outcome. To determine the impact on health care professionals across Europe due to the integration of ePROs in palliative care by measuring strain parameters etc. caused by the usage of the service which is subject of the study. Furthermore, to contribute to the evidence-base of the effectiveness of ePROs for palliative care for children with cancer Once at the end of the overall course of the study or earlier given the case of changing study staff.
See also
  Status Clinical Trial Phase
Active, not recruiting NCT03936465 - Study of the Bromodomain (BRD) and Extra-Terminal Domain (BET) Inhibitors BMS-986158 and BMS-986378 in Pediatric Cancer Phase 1
Recruiting NCT04899505 - Evaluation of the Impact of Chemotherapy on Body Odor in Adolescents and Young Adults in Oncology
Recruiting NCT03465592 - Trial of Nivolumab Following Partially Human Leukocyte Antigen (HLA) Mismatched BMT in Children & Adults With Sarcoma Phase 1/Phase 2
Recruiting NCT03373656 - Vaccination for Children of H&O and Their Parents N/A
Recruiting NCT05481502 - An Exploratory Study to Evaluate Immune Determinants of the Response to Adoptive Cell Therapy (ACT) in Solid and Hematologic Tumors N/A
Recruiting NCT05042479 - Using of Virtual Reality to Relieve Procedural Pain in Pediatric Oncology. N/A
Not yet recruiting NCT06441331 - Phase I Trial to Determine the Dose and Evaluate the PK of Lutetium Lu 177 Edotreotide Therapy in Pediatric Participants With SSTR-positive Tumors Phase 1
Recruiting NCT04471961 - Analyse of Tumour and Constitutional DNA for the Study of the Determinism in Child Neoplasia N/A
Recruiting NCT04485416 - Pilot Trial of Eltrombopag in Patients Undergoing Chemotherapy for Malignant Solid Tumors Phase 1
Active, not recruiting NCT03086421 - Social Emotional Development in Young Children With Cancer
Not yet recruiting NCT06389357 - Return to School Adaptation Programme for Children With Cancer N/A
Terminated NCT04671901 - A Study of Romiplostim to Prevent Low Platelet Counts in Children and Young Adults Receiving Chemotherapy for Solid Tumors Phase 2
Not yet recruiting NCT05633719 - Multicenter, Prospective Observational Study for Early Diagnosis, and Development of Follow-up Protocol and Hearing Rehabilitation Program for Ototoxic Hearing Loss After Chemotherapy for Pediatric Solid Cancer

External Links